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Differential Proteomics of Plasma and Tissues
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Abstract The usage of biomarkers reflecting atherosclerosis progression is impor-
tant for preventing serious incidence of cardiovascular events. To elucidate clini-
cally relevant molecular determinants in atherosclerosis, we have taken a
comprehensive approach to combine mass spectrometry-based differential proteo-
mics using both clinical and animal model specimens. Clinical plasma samples
were collected from patients with acute myocardial infarction (AMI), stable angina
(SA), and healthy/low-risk individuals (H-LR). We also obtained plasma and
arterial tissue samples from apolipoprotein E-deficient and wild-type mice at
various pathognomonic points of age. Cleavable isotope-coded affinity tags were
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used for differential mass spectrometry. Differential proteomics of clinical plasma
samples revealed that more than 10 proteins appeared to be upregulated (relative
abundance AMI/H-LR or SA/H-LR >1.5) and 5 proteins downregulated (AMI/H-
LR or SA/H-LR <1/1.5). These trends associated with the disease progression are
not always coincident with those of mouse ortholog proteins, suggesting a patho-
physiological difference between humans and the mouse model. Among the
downregulated proteins, the complement factor D (CFD) showed monotonic
decrease that was in good agreement with the enzyme-linked immunosorbent
assay. These results suggest that the comprehensive and systematic proteomic
approach may be promising in terms of the selection and evaluation of biomarker
candidates.
Keywords Proteomic study • Atherosclerosis • Inflammation • apoE-deficient
mouse
10.1 Introduction
Atherosclerosis is a chronic inflammatory disease and often causes subsequent
thrombotic complication. It is well known as a main etiology of critical diseases
such as acute coronary syndrome including myocardial infarction, sudden cardiac
death, and stroke [1]. To detect the signs of severe incidences, it is important to
accurately evaluate the progression stages of atherosclerosis, vulnerability, and
rupture risk of atherosclerotic plaques. Therefore, a variety of approaches to
establish novel biomarkers directly reflecting the status of atherosclerosis have
been conducted to date [2]. However, due to the complexity of the disease,
discovery and clinical validation of such biomarkers are still underway in many
institutions.
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Disease proteomics is a profiling technology using mass spectrometry that
makes it possible to identify disease-related alteration of protein expression com-
prehensively in a wide variety of biological specimens including serum or plasma
or extracts from tissues of interests [3]. Numerous studies have been conducted
to develop biomarkers for early diagnosis, selection of appropriate therapy, and
prognosis assessment. A decade of progress to determine changes in disease-related
protein expression has achieved accurate and high-throughput quantification of the
individual proteins within mixtures by using differential stable isotopic labeling,
such as cleavable isotope-coded affinity tags (cICATs) [4]. Either light or heavy
cICATs are labeled at the free thiol groups of cysteine residues of which proteins
are isolated from two distinct samples (i.e., disease and healthy states). The ratio of
protein amount between these states is estimated by comparing MS signal intensity
of the corresponding proteolytic peptide fragments [4].
To elucidate clinically relevant molecular determinants in atherosclerotic devel-
opment, we have taken a comprehensive approach by using mass spectrometry-
based differential proteomics. First, we conducted differential human plasma pro-
teomic studies using clinical samples of patients with atherosclerosis-related car-
diovascular disease and healthy (or low-risk) volunteers. Second, to validate the
results we obtained in the studies, a biomarker candidate, the complement factor D
(CFD) level of patients with atherosclerosis-related cardiovascular disease, was
determined by carrying out an enzyme-linked immunosorbent assay (ELISA).
Then, we tried combining differential proteome of plasma and arterial tissue
obtained from both wild-type (WT) and apoED mice at four pathognomonic time
points of age. Finally, we compared identified proteins in humans with mouse
plasma proteome.
10.2 Materials and Methods
This study was approved by the Ethics Committee of Hokkaido University Hospital
(no. 010–0118) and the institutional ethics committees of Hitachi, Ltd. Clinical
plasma samples were collected prospectively for 48 acute myocardial infarction
(AMI) patients, 73 stable angina (SA) patients, and 69 healthy/low-risk (H-LR)
individuals.
Animal care and animal experiments were conducted at Japan SLC, Inc. (Hama-
matsu, Japan), under the approval of the company’s animal care committee. The
apoED (C57BL/6.KOR/StmSlc-Apoeshl) and WT (C57BL/6) mice were fed a
high-fat diet from 8 weeks of age. Plasma and arterial tissues were collected from
each group of male or female mice at ages of 12, 18, 25, and 35 weeks.
Proteins prepared from plasma or arterial tissue as described above were labeled
with isotope-coded affinity tags using the Cleavable ICAT® Reagent Kit (Applied
Biosystems, Foster City, USA) according to the manufacturer’s instructions with
minor modifications. Tryptic peptides were applied to the strong cation exchange
(SCX) column, and the eluted solution was fractionated into 25 fractions. The SCX
separated fractions were analyzed using NanoFrontier LD, a liquid chromatograph
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mass spectrometry (LC-MS) system (Hitachi High-Technologies Corporation,
Tokyo, Japan). Original MS/MS peak lists (PLs) were generated using built-in PL
generation software in the mass spectrometer, and further protein/peptide identifi-
cation and cICAT quantitative analyses were conducted using a custom developed
software platform with a relational database.
Plasma CFD levels were measured with the use of ELISA kits according to the
manufacturer’s instructions (Quantikine, DFD00, R&D Systems, Inc., Minneapolis,
USA). Plasma levels of known markers including high-sensitive C-reactive protein
(hsCRP), amino-terminal pro-brain natriuretic peptide (NT-pro BNP), and
adiponectin were also determined (SRL, Inc., Tokyo, Japan).
10.3 Results and Discussion
Atherosclerosis is a chronic inflammatory disease, in which atherosclerotic lesions
are formed in blood vessels through complicated molecular processes occurring
between the circulating blood stream and lesions. To identify proteins showing
changes in expression levels associated with atherosclerotic plaque progression, we
Fig. 10.1 Entire research workflow of stage-dependent, mass spectrometry-based differential
proteomics. (a) Clinical proteomic study using human plasma samples. (b) Animal model prote-
omic study using plasma and arterial tissue samples from WT and atherosclerotic model mice
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conducted mass spectrometry-based proteomic analyses. Figure 10.1 shows an
overall picture of the proteomic experiments we have done. Most previous prote-
omic studies have focused on only one point of the disease. However, these
strategies would not be adequate to indentify proteins showing serial quantitative
change in accordance with progression of atherosclerosis. In this study, we
conducted a differential proteome study at several characteristic points of disease
stage and compared the results of identified proteins. The proteins we identified that
showed changes in plasma level according to the severity of the atherosclerosis-
related disease (e.g., ischemic heart disease) or atherosclerosis progression of the
mouse model might be diagnostic or predictive biomarker candidates for blood
testing. On the other hand, the proteins that showed changes, especially an increase
tendency, in arterial tissues might be biomarkers for diagnostic imaging.
10.3.1 Disease Stage-Dependent Differential Proteome
in Human Plasma
As shown in Fig. 10.1, we conducted disease stage-dependent differential human
plasma proteomic experiments using clinical samples. We selected three clinical
conditions, H-LR, SA, and AMI (Table 10.1). Two independent age-matched
plasma pools from each group (n¼ 7) were used for the experiments with combi-
nations of H-LR vs. SA, H-LR vs. AMI, and SA vs. AMI. Table 10.2 shows the
summary of identified proteins by differential proteomics of clinical plasma sam-
ples. We identified about 110 proteins in each trial of differential proteome and
found that 8–13 proteins appeared to be upregulated (relative abundance AMI/H-
LR or SA/H-LR>1.5), and 2–8 proteins were downregulated (AMI/H-LR or SA/H-
LR <1/1.5). Finally, five identical proteins were identified in common between
trials 1 and 2. Three were blood coagulation related, such as von Willebrand factor,
and the other two were categorized as structural-integrity-related or immuno-
response (immunoglobulin)-related proteins. The downregulated proteins identified
in common between trials were found to be apolipoproteins involving cholesterol
homeostasis, blood coagulation, and CFD.
To validate the results we obtained in the differential proteome experiments as
described above, we determined the CFD level of plasma of clinical samples by
ELISA as a representative example. We found that CFD levels in plasma of the
AMI group were the lowest among the three clinical groups. The statistical
Table 10.1 Description of three clinical groups in human plasma proteome







Risk and progression stage
of atherosclerosis
Low Moderate/early High/advanced
10 Discovery and Evaluation of Biomarkers for Atherosclerosis 135
difference of AMI to H-LR was the most pronounced (H/LR vs. AMI,
p¼ 2.4 1010; H/LR vs. SA, p¼ 0.54). The diminished plasma levels of CFD
in AMI patients showed that the results we obtained in our proteomic study were
basically verified. Furthermore, the plasma CFD levels showed no correlation with
body mass index (BMI) (r¼ 0.03, P< 0.05), hsCRP (r¼0.09, P< 0.05),
NT-proBNP (r¼0.03, P< 0.05), and adiponectin (r¼ 0.11, P< 0.05). In recent
years, it has been suggested that the activation of the complement system plays a
role in atherosclerosis progression [5]. Among the components of the complement
pathway, CFD is known as a key regulatory serine protease of the alternative
complement pathway. CFDmRNA and protein are abundantly expressed in adipose
tissue, and the protein is found at high levels in serum [6]. CFD expression levels in
rodent models of obesity are reduced [7]. Our results may suggest some kind of
CFD implication in atherosclerosis.
10.3.2 Disease Stage-Dependent Differential Proteome
in Atherosclerosis Mouse Model
As shown in Fig. 10.1, we conducted differential proteome experiments using
plasma and arterial tissues of WT and apolipoprotein E-deficient (apoED) mice.
Table 10.3 shows phenotypic characteristics of atherosclerotic lesions of WT and
apoED at each point of age. As we previously demonstrated, on a high-fat diet,
early lesions were observed in apoED at 12–18 weeks of age, and advanced lesions
were prominent at 25–35 weeks. No atherosclerotic lesions were found in WT mice
throughout four points of age [8]. At 25 weeks of age, vulnerable atheromatous
lesions were more abundant, but fibroatheromatous lesions were less at 25 weeks
than those at 35 weeks [8]. Table 10.4 shows a summary of identified proteins. In
plasma, the total number of identified proteins and the ratio of their upregulated
Table 10.2 Up- or downregulated proteins detected by differential proteomic analysis in clinical
pooled plasma samples
Group SA/H-LR AMI/H-LR AMI/SA
Total number of identified proteins Trial 1 116 115 110
Trial 2 106 112 114
Upregulated Trial 1 8 8 5
Trial 2 7 8 13
Common 1 5 2
Downregulated Trial 1 4 6 8
Trial 2 7 2 5
Common 2 1 1
H-LR group of healthy control and low-risk volunteers, SA group of patients with stable angina,
AMI group of patients with acute myocardial infarction, Upregulated proteins showed expression
ratio >1.5, Downregulated proteins showed expression ratio <1/1.5
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proteins (expression ratio, apoED/WT;> 1.5) did not significantly change through-
out the time course (Table 10.4). However, the ratio of downregulated proteins
(apoED/WT; <1/1.5) increased on and after 25 weeks of age (Table 10.4). We
finally found 100 proteins in the plasma, and 390 proteins in the arterial tissues were
detected throughout all four time points: 29 were identified in common between
plasma and arterial tissues [data not shown, 9]. Interestingly, we found that disease
stage-dependent quantitative variation patterns did not always correspond between
plasma and arterial tissues. Furthermore, proteins showed characteristic change in
abundance in plasma, and/or arterial tissues were found to be components of
inflammation, thrombus formation, and vascular remodeling [9].
10.3.3 Comparison Between Human and Mouse Plasma
Proteome
In this study, we conducted disease stage-dependent differential proteome experi-
ments in two identical studies: one for human plasma proteome using clinical
samples and one for plasma/arterial tissue proteome using an atherosclerotic
mouse model, apoED. Importantly, we found that the changes associated with the
disease progression in the amount of identified proteins were not always coincident
Table 10.4 Summary of up- or downregulated proteins detected in plasma and arterial tissues by
differential proteome of mouse model
Plasma Arterial tissue
Age (weeks) 12 18 25 35 12 18 25 35
Total number of identified proteins 146 133 119 124 446 616 659 693
Upregulated (%) 7 14 15 11 8 6 16 16
Downregulated (%) 5 5 11 15 2 5 8 9
No change (%) 88 81 74 74 90 89 76 75
Upregulated expression ratio (apoED/WT)>1.5,Downregulated expression ratio (apoED/WT)<
1/1.5, No change 1/1.5< expression ratio (apoED/WT)< 1.5. This table is modified from refer-
ence [9]
Table 10.3 Description of possible progression stages of atherosclerotic lesion of atherosclerosis
mouse model
Age (weeks) 12 18 25 35
Risk and progression stage
of atherosclerosis
WT None None None None













10 Discovery and Evaluation of Biomarkers for Atherosclerosis 137
with those of mouse ortholog proteins in plasma or arterial tissues determined by
proteomic studies (data not shown). In case of CFD, the plasma level of CFD in
humans determined in the proteomic study or ELISA decreased in accordance with
the severity of the clinical conditions. On the other hand, the plasma level of CFD
in mice showed a slight but not significant decreasing tendency determined in
differential proteome between WT mice and the apoED mouse model. We prelim-
inarily determined the plasma level of CFD in mice by ELISA and detected no
statistical significance between WT mice and apoED throughout all four time
points. CD5L, a soluble member of the scavenger receptor cysteine-rich domain
superfamily protein, did not show any significant change in abundance as deter-
mined by human plasma differential analyses. However, the expression ratios
(apoED/WT) of CD5L in mouse plasma were high throughout the four time points
[9]. In addition, we found that CD5L accumulated in advanced lesions of apoED in
accordance with macrophage infiltration by immunohistochemistry. These results
suggest that fundamental mechanisms of atherosclerosis development are similar to
each other; however, there would be a pathophysiological difference between
humans and the mouse model.
10.3.4 Limitation
We failed to detect several known atherosclerotic plaque-related proteins such as
cytokines, monocyte chemoattractant protein-1 (MCP-1), and intercellular adhe-
sion molecule-1(ICAM-1). We assume that there were several technical reasons for
this. For example, the practical detection limit in our mass spectrometry system was
assumed to be 1–10 ng/mL, which is much higher than the normal concentration of
cytokines. We used cICAT labeling reagents, which covalently bind only to
cysteine residues of targeted proteins. Therefore, it becomes difficult to detect
proteins with trypsin-digested peptides with few or no cysteine residues.
10.4 Conclusion
To identify proteins showing changes in expression levels associated with athero-
sclerotic plaque progression, we conducted mass spectrometry-based proteomic
analyses. We adopted two separate study designs: one for human plasma differen-
tial proteome using clinical samples and one for mouse plasma/arterial tissue
differential proteome using samples obtained from wild-type mice and an athero-
sclerotic mouse model apoED. Then several proteins showing quantitative changes
in accordance with disease were found, including the complement factor D (CFD).
The diminished plasma levels of CFD in acute myocardial infarction patients were
verified in an enzyme-linked immunosorbent assay. These results suggest that CFD
might be a potential biomarker for atherosclerosis. The comprehensive and
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systematic proteomic approach using different states of samples is promising in
terms of the selection of biomarker candidates.
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